Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	2/9/1961
Sex:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Alzheimer's Disease Markers, CSF

ARUP test code 3017653

Phospho-Tau(181)/Abeta42 Ratio, CSF	0.031	H	(Ref Interval: <=0.023)

The specimen submitted for testing did not meet ARUP submission guidelines. Testing was performed on a specimen NOT submitted in low-bind tube upon client's request. Abeta42 peptides adsorb to the surface of plastic tubes and may cause a falsely low Abeta42 concentration. Interpret results with caution.

A positive result, defined as pTau181/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder.

The pTau181 concentration was 11.1 pg/mL (Central 95%: 8.5 - 40.9 pg/mL) and the Abeta42 concentration was 362 pg/mL (Central 95%: 514 - >2500 pg/mL). These assays are not intended to be used as stand-alone tests. The ratio of pTau181/Abeta42 should be used for clinical interpretation. Provided ranges for the individual components are based on the central 95% of cognitively normal healthy controls and not intended to be used for interpretation for specific clinical conditions.

Total-Tau/Abeta42 Ratio, CSF	0.434	H	(Ref Interval: <=0.280)

The specimen submitted for testing did not meet ARUP submission guidelines. Testing was performed on a specimen NOT submitted in low-bind tube upon client's request. Abeta42 peptides adsorb to the surface of plastic tubes and may cause a falsely low Abeta42 concentration. Interpret results with caution.

A positive result, defined as tTau/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder.

The tTau concentration was 157 pg/mL (Central 95%: 103 - 375 pg/mL) and the Abeta42 concentration was 362 pg/mL (Central 95%: 514 - >2500 pg/mL). These assays are not intended to be used as stand-alone tests. The ratio of tTau/Abeta42 should be used for clinical interpretation. Provided ranges for the individual components are based on the central 95% of cognitively normal healthy controls and not intended to be used for interpretation for specific clinical conditions.

Interpretive information: Total-Tau/Abeta42 Ratio, CSF

H=High, L=Low, *=Abnormal, C=Critical

CSF panel is intended for use in adult patients aged 55 years and older being evaluated for Alzheimers disease (AD) and other causes of cognitive impairment. The pTau181/Abeta42 and tTau/Abeta42 ratios provide better concordance with amyloid positron emission tomography (PET) imaging when compared to Abeta42, pTau181, and tTau individually.

Limitations: Failure to adhere to the sample collection instructions provided in the Lab Test Catalog may result in falsely reduced Abeta42 concentrations and therefore false elevations in the reported ratios. The ratios reported have not been established for predicting development of dementia or other neurologic conditions or for monitoring responses to therapies. Results of this test must always be interpreted in the context other clinical diagnostic evaluations and should not be used alone to establish a diagnosis of AD or other cognitive disorder.

Methodology: Roche Diagnostics Inc. electrochemiluminescence assay was used. Results obtained with different assay methods or kits may be different and cannot be used interchangeably.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Phospho-Tau(181)/Abeta42 Ratio, CSF	25-223-401330	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total-Tau/Abeta42 Ratio, CSF	25-223-401330	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical